KPV Peptide
Four exact PubMed searches found no clinical trial of KPV (checked 24 Aug 2026). Four exact ClinicalTrials.gov searches also found none. Mouse and human-cell studies found effects on inflammation. They did not treat people.
What is KPV peptide?
KPV is Lys-Pro-Val, the last three parts of alpha-MSH (PMID 18061177; checked 24 Aug 2026). PubMed's NLM data gives the name MSH (11-13) and CAS 67727-97-3.
GSRS found no exact match for KPV, alpha-MSH(11-13), or MSH (11-13) (checked 24 Aug 2026). NLM still provides a CAS for the page.
KPV is not Melanotan-2. PMID 12750433 says KPV acted differently from core MSH peptides. It was unlikely to act through melanocortin receptors.
What human evidence is available?
| Evidence | What was found | What it does not show |
|---|---|---|
| People | No clinical trial in four exact PubMed searches | No human effect or safety rate |
| Human gut cells | Lower inflammation signals and cytokine release | Not treatment in people |
| Human skin outside the body | Measured movement through small holes in skin | Not a result in people |
| Mice | Colitis, weight recovery, inflammation, and survival findings | Not a human result |
No human side-effect table was found. A study of cells or skin is not a trial in people.
What did the two mouse-colitis models find?
PMID 18092346 tested KPV in two mouse models of gut inflammation (checked 24 Aug 2026). In the DSS model, treated mice got well sooner and regained more weight.
Fewer inflammatory cells entered the tissue, and colon MPO activity fell. The other model also showed recovery, weight regain, and less tissue inflammation.
In mice without a working MC1 receptor, KPV saved all animals in the treated group from death. The abstract does not give the group count.
PubMed marks non-US government support but lists no grant. Funding in the full paper was not checked.
What did the PepT1 study find?
PMID 18061177 used human gut-lining cells, human T cells, and two mouse models (checked 24 Aug 2026). KPV blocked NF-kappaB and MAP-kinase signals. It lowered the release of inflammatory cytokines.
PepT1 carried KPV into immune and gut cells. KPV also lowered inflammatory cytokine expression in mice.
NIH RePORTER links the paper to four NIDDK projects: R24DK064399, R01DK071594, R01DK061941, and R01DK055850.
What did the human-skin study measure?
PMID 28343991 used human skin outside the body (checked 24 Aug 2026). KPV did not pass through on its own at a level the test could see.
Microneedles raised movement to 4.4 µg/cm²/h. Electric current and the combined method raised the rate 8-fold and 35-fold versus microneedles alone.
This measured movement through tissue. It did not measure an effect or side effect in a person.
PubMed marks US government non-PHS support but gives no grant code. Funding in the full paper was not checked.
What does evidence tier C mean here?
KPV has mouse, cell, and tissue evidence. No human clinical trial was found. Tier C stays right (checked 24 Aug 2026).
Alpha-MSH and Melanotan-2 results do not raise KPV's tier.
What is the recorded EU status?
The EU Commission index has no exact entry for KPV or alpha-MSH(11-13) (Union Register index; checked 24 Aug 2026). The EU field stays unclear.
Why is the first-observed field null?
The primary papers show lab work, not a date for grey-market circulation. This review found no accepted circulation document (checked 24 Aug 2026).
The field stays null. A publication date is not substituted for a circulation date.
What does this register entry cover?
This entry covers the Lys-Pro-Val tripeptide KPV. It does not cover alpha-MSH or Melanotan-2.
→ Melanotan II register entry → What can be in a vial → All register entries